Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) saw unusually-high trading volume on Tuesday . Approximately 133,137 shares traded hands during mid-day trading, an increase of 43% from the previous session's volume of 92,853 shares.The stock last traded at $20.88 and had previously closed at $21.00.
Analyst Ratings Changes
ORKA has been the subject of several analyst reports. Lifesci Capital assumed coverage on shares of Oruka Therapeutics in a research report on Monday, September 16th. They set an "outperform" rating and a $41.00 price target for the company. Stifel Nicolaus initiated coverage on Oruka Therapeutics in a report on Friday, October 11th. They set a "buy" rating and a $49.00 target price for the company. TD Cowen began coverage on Oruka Therapeutics in a research note on Monday, September 16th. They issued a "buy" rating on the stock. Leerink Partnrs raised Oruka Therapeutics to a "strong-buy" rating in a research note on Tuesday, September 17th. Finally, Jefferies Financial Group assumed coverage on shares of Oruka Therapeutics in a report on Friday, September 13th. They issued a "buy" rating and a $40.00 target price on the stock. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $43.17.
View Our Latest Analysis on ORKA
Oruka Therapeutics Stock Performance
The firm's 50 day moving average price is $24.42. The company has a market capitalization of $739.53 million, a PE ratio of -3.37 and a beta of 0.78.
Institutional Trading of Oruka Therapeutics
Large investors have recently bought and sold shares of the company. Geode Capital Management LLC purchased a new position in shares of Oruka Therapeutics in the 3rd quarter valued at approximately $343,000. The Manufacturers Life Insurance Company bought a new position in Oruka Therapeutics in the third quarter worth $1,037,000. Wellington Management Group LLP purchased a new position in Oruka Therapeutics during the third quarter valued at $2,013,000. Janus Henderson Group PLC purchased a new position in Oruka Therapeutics during the third quarter valued at $5,840,000. Finally, Redmile Group LLC bought a new stake in shares of Oruka Therapeutics during the 3rd quarter valued at $10,091,000. 56.44% of the stock is owned by institutional investors.
About Oruka Therapeutics
(
Get Free Report)
ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products.
Featured Articles
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
